Reducing Time-to-Market: Why the Development Structure Matters More Than the Tooling
Reducing Time-to-Market: Why the Development Structure Matters More Than the Tooling
8
CEO & Founder bei Labtree GmbH
Long development timelines are usually blamed on complexity. More often they come from structure: isolated steps, sequential handovers and decisions made late. Digital tools improve transparency, but the development logic is what actually shortens the timeline.
Topics on this page
The topic is short and compact
Time-to-market is set mostly by the development structure, not by the tooling around it.
Digital tools support transparency, documentation and alignment; the development logic remains the central factor.
Starting from a real base, bringing samples forward and handling steps in parallel supports up to 50% faster time-to-market.
Long timelines are rarely caused by a single slow step. They accumulate from a structure in which steps are sequential and decisions are made late. A few patterns are common:
Development into the unknown: starting a formulation from a blank page extends the earliest and most uncertain phase, before anything physical exists to assess.
Sequential handovers: where formulation, packaging, design, regulatory work and production sit with separate partners, each handover couples one timeline to the next.
Late physical evidence: when a first real sample arrives late, adjustment loops happen late, when they are most expensive in time.
The result is a timeline that is longer than the underlying work requires. The opportunity is to change the structure, not only to work faster within it.
Where the time actually goes
Long timelines are rarely caused by a single slow step. They accumulate from a structure in which steps are sequential and decisions are made late. A few patterns are common:
Development into the unknown: starting a formulation from a blank page extends the earliest and most uncertain phase, before anything physical exists to assess.
Sequential handovers: where formulation, packaging, design, regulatory work and production sit with separate partners, each handover couples one timeline to the next.
Late physical evidence: when a first real sample arrives late, adjustment loops happen late, when they are most expensive in time.
The result is a timeline that is longer than the underlying work requires. The opportunity is to change the structure, not only to work faster within it.
What digital infrastructure does and does not solve
Digital infrastructure has become a significant part of the conversation about time-to-market. Connected platforms link data flows between brands and suppliers, and this brings real benefits. It is worth being precise about what they address.
Aspect | What digital tools support | What the development structure determines |
|---|---|---|
Transparency | Visibility of status and documentation across steps | How many steps and handovers exist in the first place |
Alignment | Shared, current information between parties | Whether the parties are integrated or separate |
Timeline | Less time lost to coordination and chasing | How early development starts from a real base, and how much runs in parallel |
Digital tools support transparency, documentation and alignment in the development process. The underlying development logic remains the central factor. A connected data flow makes a structure more legible, but the structure itself, sequential or parallel, integrated or fragmented, is what sets the timeline.
The structural levers that shorten the timeline
If structure sets the timeline, then the levers that shorten it are structural. Three matter most:
Start from a real formulation base: beginning from a pre-qualified base rather than a blank page removes the longest and most uncertain part of the earliest phase.
Bring physical evidence forward: early physical samples move adjustment loops to the start of the project, where they are faster and cheaper to resolve.
Handle steps in parallel: packaging, design and regulatory preparation considered early and in parallel with formulation development, rather than only after final approval, removes sequential coupling. Final regulatory approval and final production necessarily follow final formulation approval, but the preparation for them can run alongside.
These levers are about the structure of development, not the speed of any single step. Together they are what makes a meaningfully faster timeline possible. The same logic applies when a brand scales, as covered in our note on contract manufacturer management: fewer interface breaks mean a shorter, more predictable path.
Positioning time-to-market as a structural decision
The strategic shift is to treat time-to-market as a structural property of how a product is developed, not as something to be optimised after the fact. Three principles tend to hold up:
Choose the structure deliberately: decide early whether development starts from a real base and runs in parallel, because that decision sets most of the timeline.
Use tools to support, not to substitute: digital tools improve transparency within a structure, but they do not replace a sound development logic. A clear data flow over a fragmented structure still leaves the fragmentation.
Keep speed and substance together: a faster timeline is only valuable if the product still holds up, so the structure should shorten the path without skipping validation.
Positioned this way, time-to-market becomes a decision made at the start of development, not a metric chased at the end. For a new brand, the related route of white label for fast market entry shows the same structural advantage in practice.
How Labtree supports up to 50% faster time-to-market
Labtree's model is built around the structural levers rather than around tooling. The starting point is a real formulation base. Over 1,000 own formulations give a brand a concrete starting point, so development does not begin in the unknown, removing the longest part of the earliest phase.
Physical samples of pre-qualified formulations ship within 24 hours from the sample warehouse, free of charge for standard samples, so adjustment loops happen early on a real product rather than late on a specification. Packaging, design, regulatory requirements and production capability are considered early and in parallel with formulation development, rather than addressed only after final formulation approval, which removes sequential coupling. Together these support up to 50% faster time-to-market, through existing formulation bases plus parallel implementation.
Digital tools support transparency and documentation across this process, while the development logic remains the central factor. The timeline is shortened by the structure, with the tooling making that structure legible rather than creating the speed.
The 5-phase process applied to a faster launch
Conception: matching the product idea to a suitable base from the 1,000+ formulation pool, so development starts from a real base rather than a blank page.
Sampling: standard samples of pre-qualified formulations within 24 hours, so the first physical assessment happens at the start of the project.
Individualisation: adapting the base to the brand's specifications, with early adjustment loops resolved on real samples.
Prototyping: a production-near test batch, with packaging, design, regulatory requirements and production capability considered early and in parallel rather than only after final formulation approval.
Production: scaling to the initial batch and into routine production, with a shorter, more predictable path because the structure reduced sequential coupling.
Own formulation base: a large pool of own formulations, so development starts from a real base rather than the unknown.
Sampling speed: samples within 24 hours, with free standard shipping, so adjustment loops happen early.
Parallel handling: packaging, design and regulatory preparation considered in parallel with formulation development, not only after final approval.
Few interface breaks: formulation and production in one workflow, so timelines are not coupled across separate partners.
Balanced use of tools: digital tools used to support transparency and documentation, with the development logic as the central factor.
Time-to-market in cosmetics is set more by the structure of development than by the tooling around it. Isolated steps, sequential handovers and late physical evidence extend timelines, while starting from a real base, bringing samples forward and handling steps in parallel shorten them. Digital tools support transparency and alignment, but the development logic remains the central factor. A structure built around a real formulation base, early samples and parallel implementation is what makes up to 50% faster time-to-market a plannable outcome rather than a hope.
More useful links
FAQ
Does Labtree have its own laboratory?
Yes. Labtree has its own development competence including a laboratory. This means formulations are not only selected but specifically developed, tested and adapted. In addition, smaller test batches can be produced in-house to validate products early under real conditions and move them safely into production.
Why does cosmetic development take so long?
Timelines that run from one to several years are often driven less by the work itself than by structure: development starting from a blank page, sequential handovers between separate partners, and physical samples arriving late. These extend the timeline beyond what the underlying work requires.
Do digital tools reduce time-to-market?
They help. Connected data flows and digital tools support transparency, documentation and alignment, which reduces time lost to coordination. But the development logic remains the central factor. Tools make a structure more legible; the structure itself, sequential or parallel, determines the timeline.
How much faster can development be?
Labtree supports up to 50% faster time-to-market through existing formulation bases plus parallel implementation. In concrete terms, a white-label route with standard packaging is typically 2 to 3 months, and an individual new development usually 3 to 6 months, depending on stability testing, regulatory preparation and packaging availability.
What is the single biggest lever on the timeline?
Starting from a real formulation base rather than a blank page. It removes the longest and most uncertain part of the earliest phase. Bringing physical samples forward and handling packaging, design and regulatory preparation in parallel then reduce sequential coupling.
Does a faster timeline mean less validation?
No. The structure shortens the path without skipping validation. Final regulatory approval and final production necessarily follow final formulation approval. The speed comes from starting on a real base and running preparatory steps in parallel, not from omitting stability testing or regulatory work.
Now discover more articles
